BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice

Neuroscience

Volumn 180, Issue , 2011, Pages 293-304

  Hutter Saunders, J A L ^a   Kosloski, L M ^a   McMillan, J M ^a   Yotam, N ^b   Rinat, T ^b   Mosley, R L ^a   Gendelman, H E ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b BIOLINERX LTD   (Israel)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Behavior; Dopamine; Motor function; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID PLUS LEVODOPA; ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BL 1023; CARBIDOPA; DOPAMINE; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELL SURVIVAL; DRUG COMBINATIONS; GAMMA-AMINOBUTYRIC ACID; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS;

EID: 79953195455     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.02.015     Document Type: Article

References (40)

1. Agid Y. Levodopa: is toxicity a myth?. Neurology 1998, 50:858-863.
2. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004, 101:9435-9440.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
4. Boska M.D., Lewis T.B., Destache C.J., Benner E.J., Nelson J.A., Uberti M., Mosley R.L., Gendelman H.E. Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J Neurosci 2005, 25:1691-1700.
5. Carbone D.L., Moreno J.A., Tjalkens R.B. Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP. Brain Res 2008, 1217:1-9.
6. Chartoff E.H., Marck B.T., Matsumoto A.M., Dorsa D.M., Palmiter R.D. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A 2001, 98:10451-10456.
7. Contin M., Martinelli P. Pharmacokinetics of levodopa. J Neurol 2010, 257:S253-S261.
8. Creese I., Iversen S.D. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res 1973, 55:369-382.
9. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
10. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 2005, 252(Suppl 4):IV37-IV42.
11. Fariello R.G. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs 1998, 55(Suppl 1):10-16.
12. Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res 1996, 741:142-152.
13. Graybiel A.M., Canales J.J., Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000, 23:S71-S77.
14. Hutter Saunders J.A.L., Gendelman H.E., Mosley R.L. Evaluation of murine motor and behavior functions following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. J Neuroimmune Pharmacol 2011, in press.
15. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151.
16. Khor S.P., Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007, 2:234-243.
17. Kitanaka J., Kitanaka N., Tatsuta T., Takemura M. 2-Phenylethylamine in combination with l-deprenyl lowers the striatal level of dopamine and prolongs the duration of the stereotypy in mice. Pharmacol Biochem Behav 2005, 82:488-494.
18. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
19. Kuroda H. Gamma-aminobutyric acid (GABA) in cerebrospinal fluid. Acta Med Okayama 1983, 37:167-177.
20. Levy R., Lang A.E., Dostrovsky J.O., Pahapill P., Romas J., Saint-Cyr J., Hutchison W.D., Lozano A.M. Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. Brain 2001, 124:2105-2118.
21. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
22. Luchtman D.W., Shao D., Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav 2009, 98:130-138.
23. Manyam B.V. Low CSF gamma-aminobutyric acid levels in Parkinson's disease. Effect of levodopa and carbidopa. Arch Neurol 1982, 39:391-392.
24. Melamed E., Offen D., Shirvan A., Djaldetti R., Barzilai A., Ziv I. Levodopa toxicity and apoptosis. Ann Neurol 1998, 44:S149-S154.
25. Meredith G.E., Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006, 21:1595-1606.
26. Miller R.L., James-Kracke M., Sun G.Y., Sun A.Y. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 2009, 34:55-65.
27. Nishino N., Fujiwara H., Noguchi-Kuno S.A., Tanaka C. GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease. Jpn J Pharmacol 1988, 48:331-339.
28. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984, 7:35-49.
29. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., Hirsch E.C., Farrer M., Schapira A.H., Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010, 16:653-661.
30. Oksman M., Tanila H., Yavich L. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of l-DOPA. Neuropharmacology 2009, 56:647-652.
31. Owens D.F., Kriegstein A.R. Is there more to GABA than synaptic inhibition?. Nat Rev Neurosci 2002, 3:715-727.
32. Pattarini R., Smeyne R.J., Morgan J.I. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 2007, 145:654-668.
33. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996, 93:4565-4571.
34. Rinne U.K., Laaksonen H., Riekkinen P., Sonninen V. Brain glutamic acid decarboxylase activity in Parkinson's disease. Eur Neurol 1974, 12:13-19.
35. Rozas G., Liste I., Lopez-Martin E., Guerra M.J., Kokaia M., Labandeira-Garcia J.L. Intrathalamic implants of GABA-releasing polymer matrices reduce motor impairments in rats with excitotoxically lesioned striata. Exp Neurol 1996, 142:323-330.
36. Shin J.Y., Park H.-J., Ahn Y.H., Lee P.H. Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J Neurochem 2009, 111:1042-1050.
37. Tillerson J.L., Caudle W.M., Reveron M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 2002, 178:80-90.
38. Vijitruth R., Liu M., Choi D.Y., Nguyen X.V., Hunter R.L., Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 2006, 3:6.
39. Yokoyama H., Kuroiwa H., Yano R., Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008, 29:293-301.
40. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A 2001, 98:1982-1987.